RANDOMIZED CLINICAL TRIAL
Pentavalent immunogenicity
A randomized trial compared the immune responses and safety of a pentavalent MenABCWY formulation with established comparator vaccines.
READ STUDY ↗
VACCINE PROFILE / PENTAVALENT PLATFORM
MenABCWY
Vaccines.
The science of pentavalent meningococcal immunization: combining ACWY capsular conjugate antigens with serogroup B protein-based components.
EXPLORE THE ANTIGEN DESIGN ↗
FIG 01 / PENTAVALENT ANTIGEN ATLAS
Conceptual antigen map • Not to scale
01 / PENTAVALENT IMMUNOLOGY
Five serogroups.
Two antigen strategies.
MenABCWY vaccines are pentavalent meningococcal vaccines designed to protect against invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y.
Their design combines a quadrivalent capsular polysaccharide-conjugate component with a protein-based serogroup B component. Specific antigen compositions vary between licensed products.
Scientific distinction:
Pentavalent serogroup coverage
does not mean protection
against all meningococcal strains
or every cause of meningitis.
02 / ANTIGEN ARCHITECTURE
Two complementary
immunological platforms.
COMPONENT A / ACWY
A
C
W
Y
Capsular conjugates
Polysaccharide antigens from serogroups A, C, W, and Y are linked to carrier proteins to elicit T-cell-dependent immune responses.
COMPONENT B / SEROGROUP B
B
Protein-based antigens
The serogroup B component uses selected bacterial proteins and, in some formulations, outer-membrane vesicles to stimulate bactericidal antibody responses.
03 / FORMULATION RESEARCH
Pentavalent does not mean
one identical formulation.
Different licensed pentavalent products combine established ACWY and B antigen platforms. Their compositions are not interchangeable simply because they target the same serogroups.
FORMULATION / 01
MenACWY-TT / MenB-FHbp
Combines ACWY polysaccharides conjugated to tetanus toxoid with factor H binding protein antigens for serogroup B.
Example: Penbraya
FORMULATION / 02
MenACWY-CRM / MenB-4C
Combines ACWY glycoconjugate antigens with a multicomponent serogroup B formulation containing recombinant proteins and outer-membrane vesicles.
Example: Penmenvy
04 / CLINICAL EVIDENCE
Evaluating five-serogroup
immune responses.
MenABCWY clinical trials evaluate bactericidal antibody responses, immune-response noninferiority, safety, and responses across multiple MenB strains.
PHASE III RESEARCH
Breadth of MenB response
A phase III study examined immune-response breadth against diverse meningococcal serogroup B strains within pentavalent vaccine development.
READ STUDY ↗
MULTICOUNTRY PHASE III TRIAL
Noninferiority evaluation
A multicountry randomized trial evaluated pentavalent vaccine immunogenicity and safety against separate MenACWY and MenB comparators.
READ STUDY ↗
05 / SCIENTIFIC ANSWERS
MenABCWY
essentials.
What is a MenABCWY vaccine?
A pentavalent meningococcal vaccine combining antigenic coverage directed at serogroups A, B, C, W, and Y.
How does MenABCWY differ from MenACWY?
MenABCWY includes a serogroup B component in addition to antigens targeting A, C, W, and Y. MenACWY alone does not supply that MenB coverage.
When is MenABCWY used?
Under CDC guidance, MenABCWY is an option when both MenACWY and MenB vaccination are indicated at the same visit. Eligibility and schedules are product- and region-specific.
Do MenABCWY vaccines prevent all meningitis?
No. Other meningococcal serogroups and many other infectious or noninfectious causes of meningitis remain outside their antigen coverage.
06 / EVIDENCE LIBRARY
Research and guidance.
- CDC — Types of Meningococcal Vaccines .
- CDC — Meningococcal Vaccine Recommendations .
- Randomized trial of pentavalent MenABCWY immunogenicity and safety .
- Phase III trial evaluating immune-response breadth .
- Multicountry phase III MenABCWY noninferiority trial .
Educational scientific information. Vaccination recommendations and product eligibility should follow current regional guidance and qualified medical advice.
VACCINE SCIENTIFIC CLUSTER / COMPLETE
Explore the vaccine atlas.
Compare MenACWY, MenB, MenABCWY, pneumococcal and Hib vaccine science.